Fully-Automated Calprotectin Immunoassay Validated for IBD Patients
By LabMedica International staff writers Posted on 13 Jul 2020 |
Image: The LIAISON XL is a fully automated chemiluminescence analyzer, performing complete sample processing (Photo courtesy of DiaSorin).
The incidence of inflammatory bowel disease (IBD) is increasing. This chronic intestinal inflammation disorder comprises two major forms of inflammation: Crohn’s disease (CD) and ulcerative colitis (UC). Distinction between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) based on clinical symptoms is often difficult.
Multiple studies have proven the use of calprotectin in IBD patients as a biomarker in monitoring disease activity, response to treatment and relapse. Calprotectin levels directly correlate with the amount of granulocytes present at the intestinal inflammation site, correlating with the severity of IBD. The amount of patients being screened with calprotectin for IBD is increasing to avoid unnecessary endoscopy, thus a need for an easy to use and quick laboratory assay arises.
Clinical Biochemists and their associates at the OLVG Oost Hospital (Amsterdam, the Netherlands) measured calprotectin in 303 subjects in five patient groups: IBD: ulcerative colitis (UC) and Crohn’s disease (CD); non-IBD: IBS, other gastrointestinal diseases and controls (healthy patients with no gastrointestinal disease). The patients provided fecal samples collected at home using a standard sample container provided by the laboratory. The samples were stored frozen up to one week before measuring calprotectin concentrations.
The Calprotectin Stool Extraction Device was used to prepare the stools for the Liaison calprotectin immunoassay and the fecal calprotectin immunoassay was conducted in the LIAISON XL analyzer (DiaSorin, Saluggia, Italy). This immunoassay was compared to the EliA calprotectin 2 immunoassay run on the Phadia ImmunoCAP250 (Thermo Fisher Scientific, Waltham, MA, USA).
The scientists reported that the calprotectin immunoassay of DiaSorin showed good analytical performance with frozen samples. The presence of blood in the stool can interfere with the measurement of calprotectin. Patients suffering from IBD (UC or CD) showed significant higher concentrations of fecal calprotectin compared to controls (UC:710 ± 921 mg/kg; CD:967 ± 1,243 mg/kg; controls:11 ± 8 mg/kg) using DiaSorin’s immunoassay. The remaining non-IBD groups showed no significant difference compared to controls. Follow-up of nine patients showed a significant decrease in fecal calprotectin after treatment. At 50 mg/kg cut-off value, the negative predictive value for DiaSorin’s immunoassay was 96% and the positive predictive value 83% (sensitivity of 95% and specificity of 86%).
The authors concluded that the lack of standardization contributes to the numerical differences between the two methods, but the qualitative conclusions do not differ. DiaSorin’s calprotectin immunoassay can be used both to distinguish between IBD and non-IBD patients as well as for follow-up of IBD patients. The assay has a shorter extraction time and the time of measuring is much shorter making it very suitable for laboratories with high throughput of samples. The study was published online on June 24, 2020 in the journal Practical Laboratory Medicine.
Multiple studies have proven the use of calprotectin in IBD patients as a biomarker in monitoring disease activity, response to treatment and relapse. Calprotectin levels directly correlate with the amount of granulocytes present at the intestinal inflammation site, correlating with the severity of IBD. The amount of patients being screened with calprotectin for IBD is increasing to avoid unnecessary endoscopy, thus a need for an easy to use and quick laboratory assay arises.
Clinical Biochemists and their associates at the OLVG Oost Hospital (Amsterdam, the Netherlands) measured calprotectin in 303 subjects in five patient groups: IBD: ulcerative colitis (UC) and Crohn’s disease (CD); non-IBD: IBS, other gastrointestinal diseases and controls (healthy patients with no gastrointestinal disease). The patients provided fecal samples collected at home using a standard sample container provided by the laboratory. The samples were stored frozen up to one week before measuring calprotectin concentrations.
The Calprotectin Stool Extraction Device was used to prepare the stools for the Liaison calprotectin immunoassay and the fecal calprotectin immunoassay was conducted in the LIAISON XL analyzer (DiaSorin, Saluggia, Italy). This immunoassay was compared to the EliA calprotectin 2 immunoassay run on the Phadia ImmunoCAP250 (Thermo Fisher Scientific, Waltham, MA, USA).
The scientists reported that the calprotectin immunoassay of DiaSorin showed good analytical performance with frozen samples. The presence of blood in the stool can interfere with the measurement of calprotectin. Patients suffering from IBD (UC or CD) showed significant higher concentrations of fecal calprotectin compared to controls (UC:710 ± 921 mg/kg; CD:967 ± 1,243 mg/kg; controls:11 ± 8 mg/kg) using DiaSorin’s immunoassay. The remaining non-IBD groups showed no significant difference compared to controls. Follow-up of nine patients showed a significant decrease in fecal calprotectin after treatment. At 50 mg/kg cut-off value, the negative predictive value for DiaSorin’s immunoassay was 96% and the positive predictive value 83% (sensitivity of 95% and specificity of 86%).
The authors concluded that the lack of standardization contributes to the numerical differences between the two methods, but the qualitative conclusions do not differ. DiaSorin’s calprotectin immunoassay can be used both to distinguish between IBD and non-IBD patients as well as for follow-up of IBD patients. The assay has a shorter extraction time and the time of measuring is much shorter making it very suitable for laboratories with high throughput of samples. The study was published online on June 24, 2020 in the journal Practical Laboratory Medicine.
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms